JP2013506675A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013506675A5 JP2013506675A5 JP2012532248A JP2012532248A JP2013506675A5 JP 2013506675 A5 JP2013506675 A5 JP 2013506675A5 JP 2012532248 A JP2012532248 A JP 2012532248A JP 2012532248 A JP2012532248 A JP 2012532248A JP 2013506675 A5 JP2013506675 A5 JP 2013506675A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- notch3
- notch1
- antagonist
- medicament according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 17
- 239000005557 antagonist Substances 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 208000000389 T-cell leukemia Diseases 0.000 claims 3
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 3
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000017414 Precursor T-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24729809P | 2009-09-30 | 2009-09-30 | |
| US61/247,298 | 2009-09-30 | ||
| PCT/US2010/050610 WO2011041336A2 (en) | 2009-09-30 | 2010-09-29 | Methods of treating cancer using notch antagonists |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015011573A Division JP2015145362A (ja) | 2009-09-30 | 2015-01-23 | Ｎｏｔｃｈ３アンタゴニストを用いたＮｏｔｃｈ１アンタゴニスト耐性がんの治療 |
| JP2016138236A Division JP2017014219A (ja) | 2009-09-30 | 2016-07-13 | Ｎｏｔｃｈ３アンタゴニストを用いたＮｏｔｃｈ１アンタゴニスト耐性がんの治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013506675A JP2013506675A (ja) | 2013-02-28 |
| JP2013506675A5 true JP2013506675A5 (enExample) | 2013-10-17 |
| JP6025563B2 JP6025563B2 (ja) | 2016-11-16 |
Family
ID=43127684
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012532248A Active JP6025563B2 (ja) | 2009-09-30 | 2010-09-29 | Ｎｏｔｃｈ３アンタゴニストを用いたＮｏｔｃｈ１アンタゴニスト耐性癌の治療 |
| JP2015011573A Withdrawn JP2015145362A (ja) | 2009-09-30 | 2015-01-23 | Ｎｏｔｃｈ３アンタゴニストを用いたＮｏｔｃｈ１アンタゴニスト耐性がんの治療 |
| JP2016138236A Pending JP2017014219A (ja) | 2009-09-30 | 2016-07-13 | Ｎｏｔｃｈ３アンタゴニストを用いたＮｏｔｃｈ１アンタゴニスト耐性がんの治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015011573A Withdrawn JP2015145362A (ja) | 2009-09-30 | 2015-01-23 | Ｎｏｔｃｈ３アンタゴニストを用いたＮｏｔｃｈ１アンタゴニスト耐性がんの治療 |
| JP2016138236A Pending JP2017014219A (ja) | 2009-09-30 | 2016-07-13 | Ｎｏｔｃｈ３アンタゴニストを用いたＮｏｔｃｈ１アンタゴニスト耐性がんの治療 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9200071B2 (enExample) |
| EP (1) | EP2483311B1 (enExample) |
| JP (3) | JP6025563B2 (enExample) |
| KR (1) | KR101782180B1 (enExample) |
| CN (1) | CN102630229B (enExample) |
| AU (1) | AU2010300747A1 (enExample) |
| BR (1) | BR112012007252A2 (enExample) |
| CA (1) | CA2775880A1 (enExample) |
| CL (1) | CL2012000800A1 (enExample) |
| CO (1) | CO6531430A2 (enExample) |
| CR (1) | CR20120213A (enExample) |
| EC (1) | ECSP12011858A (enExample) |
| ES (1) | ES2580229T3 (enExample) |
| IL (1) | IL218662A0 (enExample) |
| MA (1) | MA33973B1 (enExample) |
| MX (1) | MX342250B (enExample) |
| PE (1) | PE20120998A1 (enExample) |
| PH (1) | PH12012500574A1 (enExample) |
| RU (1) | RU2012117619A (enExample) |
| WO (1) | WO2011041336A2 (enExample) |
| ZA (1) | ZA201201984B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2133796C1 (ru) * | 1997-10-09 | 1999-07-27 | ОАО "Томский электромеханический завод им.В.В.Вахрушева" | Люк смотрового колодца |
| PL2032166T3 (pl) | 2006-06-13 | 2013-09-30 | Oncomed Pharm Inc | Kompozycje i sposoby diagnozowania i leczenia nowotworów |
| JP5618544B2 (ja) | 2007-01-24 | 2014-11-05 | オンコメッドファーマシューティカルズ インコーポレイテッド | 癌の診断および処置のための組成物および方法 |
| PE20090321A1 (es) | 2007-06-04 | 2009-04-20 | Genentech Inc | Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica |
| US9132189B2 (en) | 2008-07-08 | 2015-09-15 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
| CN102316897B (zh) | 2008-07-08 | 2014-11-05 | 昂考梅德药品有限公司 | Notch结合剂和拮抗剂及其应用方法 |
| WO2010146550A1 (en) | 2009-06-18 | 2010-12-23 | Pfizer Inc. | Anti notch-1 antibodies |
| JP6016800B2 (ja) | 2010-12-15 | 2016-10-26 | ワイス・エルエルシー | 抗ノッチ１抗体 |
| BR112015010436A2 (pt) * | 2012-11-07 | 2017-08-22 | Pfizer | Anticorpos anti-notch3 e conjugados anticorpo-fármaco |
| DK2935330T3 (da) | 2012-12-19 | 2019-07-22 | Aveo Pharmaceuticals Inc | Anti-notch3-antistoffer |
| WO2014159242A1 (en) * | 2013-03-14 | 2014-10-02 | Novartis Ag | Notch 3 mutants and uses thereof |
| WO2014159239A2 (en) * | 2013-03-14 | 2014-10-02 | Novartis Ag | Antibodies against notch 3 |
| HK1211322A1 (en) * | 2013-03-15 | 2016-05-20 | 昂考梅德药品有限公司 | Methods of treating pancreatic cancer |
| CA2928568A1 (en) | 2013-07-26 | 2015-01-29 | Update Pharma Inc. | Combinatorial methods to improve the therapeutic benefit of bisantrene |
| KR102030891B1 (ko) | 2014-02-12 | 2019-10-11 | 제넨테크, 인크. | 항-재기드1 항체 및 사용 방법 |
| KR20170029490A (ko) | 2014-07-11 | 2017-03-15 | 제넨테크, 인크. | 노치 경로 억제 |
| CN105585636B (zh) * | 2015-11-24 | 2020-03-03 | 南方医科大学 | 一种人NOTCH1 NICD蛋白Ser2162位点磷酸化抗体及其制备方法和应用 |
| EP3448420B1 (en) * | 2016-04-29 | 2022-09-14 | Aveo Pharmaceuticals, Inc. | Anti-notch3 antibody |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| JP4460155B2 (ja) | 1997-12-05 | 2010-05-12 | ザ・スクリプス・リサーチ・インステイチユート | マウス抗体のヒト化 |
| KR20070107687A (ko) | 2004-12-31 | 2007-11-07 | 제넨테크, 인크. | Ｂｒ３과 결합하는 폴리펩티드, 및 그의 용도 |
| AR063494A1 (es) | 2006-10-19 | 2009-01-28 | Genentech Inc | Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3 |
| CL2007002989A1 (es) | 2006-10-19 | 2008-05-16 | Genentech Inc | Anticuerpos anti-notch3; acido nucleico que los codifica; vector y celula que lo comprende; metodo de produccion; y su uso para el diagnostico de enfermedades relacionadas con notch3. |
| WO2008076960A2 (en) * | 2006-12-18 | 2008-06-26 | Genentech, Inc. | Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases |
| JP5618544B2 (ja) * | 2007-01-24 | 2014-11-05 | オンコメッドファーマシューティカルズ インコーポレイテッド | 癌の診断および処置のための組成物および方法 |
| EP2134356A2 (en) * | 2007-03-05 | 2009-12-23 | Board of Regents, The University of Texas System | Negative genetic regulation of cancer cell renewal in synergy with notch- or numb-specific immunotherapy |
| PE20090321A1 (es) * | 2007-06-04 | 2009-04-20 | Genentech Inc | Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica |
| CN102316897B (zh) * | 2008-07-08 | 2014-11-05 | 昂考梅德药品有限公司 | Notch结合剂和拮抗剂及其应用方法 |
| WO2010141249A2 (en) * | 2009-06-02 | 2010-12-09 | Merck Sharp & Dohme Corp. | Generation, characterization and uses thereof of anti-notch3 antibodies |
| WO2010146550A1 (en) * | 2009-06-18 | 2010-12-23 | Pfizer Inc. | Anti notch-1 antibodies |
-
2010
- 2010-09-29 PH PH1/2012/500574A patent/PH12012500574A1/en unknown
- 2010-09-29 JP JP2012532248A patent/JP6025563B2/ja active Active
- 2010-09-29 MA MA34797A patent/MA33973B1/fr unknown
- 2010-09-29 WO PCT/US2010/050610 patent/WO2011041336A2/en not_active Ceased
- 2010-09-29 PE PE2012000413A patent/PE20120998A1/es not_active Application Discontinuation
- 2010-09-29 KR KR1020127010886A patent/KR101782180B1/ko not_active Expired - Fee Related
- 2010-09-29 CA CA2775880A patent/CA2775880A1/en not_active Abandoned
- 2010-09-29 ES ES10762827.3T patent/ES2580229T3/es active Active
- 2010-09-29 AU AU2010300747A patent/AU2010300747A1/en not_active Abandoned
- 2010-09-29 RU RU2012117619/10A patent/RU2012117619A/ru not_active Application Discontinuation
- 2010-09-29 CN CN201080054108.9A patent/CN102630229B/zh active Active
- 2010-09-29 MX MX2012003851A patent/MX342250B/es active IP Right Grant
- 2010-09-29 BR BR112012007252-8A patent/BR112012007252A2/pt not_active IP Right Cessation
- 2010-09-29 US US13/498,560 patent/US9200071B2/en active Active
- 2010-09-29 EP EP10762827.3A patent/EP2483311B1/en active Active
-
2012
- 2012-03-15 IL IL218662A patent/IL218662A0/en unknown
- 2012-03-16 ZA ZA2012/01984A patent/ZA201201984B/en unknown
- 2012-03-30 CL CL2012000800A patent/CL2012000800A1/es unknown
- 2012-04-09 CO CO12057624A patent/CO6531430A2/es not_active Application Discontinuation
- 2012-04-26 CR CR20120213A patent/CR20120213A/es unknown
- 2012-04-30 EC ECSP12011858 patent/ECSP12011858A/es unknown
-
2015
- 2015-01-23 JP JP2015011573A patent/JP2015145362A/ja not_active Withdrawn
-
2016
- 2016-07-13 JP JP2016138236A patent/JP2017014219A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013506675A5 (enExample) | ||
| RU2012117619A (ru) | ЛЕЧЕНИЕ ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ, УСТОЙЧИВЫХ К ДЕЙСТВИЮ АНТАГОНИСТА Notch1, С ПОМОЩЬЮ АНТАГОНИСТА Notch3 | |
| RU2018108048A (ru) | Новые анти-pd-1 антитела | |
| EA033072B1 (ru) | Применение антител к семафорину 4d для лечения болезни хантингтона | |
| JP2014512809A5 (enExample) | ||
| RU2019111722A (ru) | Антитела против siglec-15 и способы их применения | |
| FI3332006T3 (fi) | Uusia anti-PD-L1-vasta-aineita | |
| EA201490957A1 (ru) | Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела | |
| AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
| NZ712765A (en) | Antibodies that bind csf1r | |
| WO2014037588A3 (en) | Methods and compounds for preventing, treating and diagnosing an inflammatory condition | |
| RU2014147867A (ru) | Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов | |
| JP2013198490A5 (enExample) | ||
| FI3799885T3 (fi) | Lymfosyyttien estoreittien neutralointi | |
| JP2017535257A5 (enExample) | ||
| JP2014205674A5 (enExample) | ||
| NZ608206A (en) | Antibodies that bind myostatin, compositions and methods | |
| JP2013542194A5 (enExample) | ||
| NZ611269A (en) | Neutralizing anti-ccl20 antibodies | |
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| RU2015126533A (ru) | Анти-cd47 антитела и способы их применения | |
| JP2013538057A5 (enExample) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| JP2014526898A5 (enExample) | ||
| JP2015511962A5 (enExample) |